* requirement for oxygen administration * shortness of breath in resting position * creatinin \> 2.0 mg/dl * women during pregnancy and lactation * participation in other clinical trials or observation period of competing trials * active or clinically significant cardiac disease including congestive heart failure (new york heart association class iii or higher) * history or current evidence of clinically significant cardiac arrhythmia except atrial fibrillation or paroxysmal supraventricular tachycardia * use of concomitant medications that prolong the qt/qtc interval * physician decision that involvement in the study is not in the patient´s best interest

* requirement for oxygen administration * shortness of breath in resting position * creatinin \> 2.0 mg/dl * women during pregnancy and lactation * participation in other clinical trials or observation period of competing trials * active or clinically significant cardiac disease including congestive heart failure (new york heart association class iii or higher) * history or current evidence of clinically significant cardiac arrhythmia except atrial fibrillation or paroxysmal supraventricular tachycardia * use of concomitant medications that prolong the qt/qtc interval * physician decision that involvement in the study is not in the patient´s best interest

- requirement for oxygen administration - shortness of breath in resting position - creatinin > 2.0 mg/dl - women during pregnancy and lactation - participation in other clinical trials or observation period of competing trials - active or clinically significant cardiac disease including congestive heart failure (new york heart association class iii or higher) - history or current evidence of clinically significant cardiac arrhythmia except atrial fibrillation or paroxysmal supraventricular tachycardia - use of concomitant medications that prolong the qt/qtc interval - physician decision that involvement in the study is not in the patient´s best interest

- requirement for oxygen administration - shortness of breath in resting position - creatinin > 2.0 mg/dl - women during pregnancy and lactation - participation in other clinical trials or observation period of competing trials - active or clinically significant cardiac disease including congestive heart failure (new york heart association class iii or higher) - history or current evidence of clinically significant cardiac arrhythmia except atrial fibrillation or paroxysmal supraventricular tachycardia - use of concomitant medications that prolong the qt/qtc interval - physician decision that involvement in the study is not in the patient´s best interest